Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis

Launched by ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE · Jul 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat early-stage acute pancreatitis, which is sudden inflammation of the pancreas. The study will compare a procedure called endoscopic pancreatic duct stenting—where a small tube is placed in the pancreas to help drainage—with the usual treatment methods. The goal is to see if this new approach is safe and works better for adults who have moderate to severe acute pancreatitis not caused by gallstones.

Adults between the ages of 65 and 74 with confirmed early pancreatitis who show signs of organ problems might be eligible to join. To participate, patients need to agree to take part and should not have other conditions requiring specific endoscopic procedures, previous surgeries on the area, pregnancy, severe shock, or certain bleeding problems. If you join the study, you will receive either the new stenting procedure or the standard care, and doctors will closely monitor your progress to understand which treatment helps more. This study is not yet recruiting participants but aims to improve treatment options for people with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of acute pancreatitis confirmed on the basis of at least 2 of the 3 diagnostic criteria according to the revised Atlanta classification
• • 2. Presence of organ failure signs (moderate and severe pancreatitis)
• • 3. Informed consent of the patient
• Exclusion Criteria:
• • 1. Presence of other indications for endoscopic intervention on the major duodenal papilla (biliary pancreatitis with cholangitis, calculus of the major duodenal papilla, stenosis of the major duodenal papilla, etc.)
• • 2. Previous surgical interventions on the major duodenal papilla
• • 3. Diverticula of the major duodenal papilla
• • 4. Pregnancy
• • 5. Shock
• • 6. Coagulopathy (INR\>1.5, blood platelets \< 50\*109/l